# OnCo record norpact-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/norpact-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "norpact-1", "NCT02919787" ;
  schema:name "NORPACT-1"@en ;
  schema:alternateName "NorPACT-1"@en, "Nordic Pancreatic Cancer Trial-1"@en ;
  schema:description "NORPACT-1 asked whether giving FOLFIRINOX chemotherapy before surgery helps people whose pancreatic cancer can be removed straight away; it did not, and patients who went straight to surgery were if anything more likely to be alive at 18 months, so upfront surgery remains the standard for clearly resectable disease."@en ;
  schema:url <https://onco.cc/trials/norpact-1/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02919787> ;
  onco:status "negative" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/irinotecan/> ;
  onco:institutions <https://onco.cc/institutions/oslo-radium-hospital/>, <https://onco.cc/institutions/karolinska/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024/> .